ResultsIQ › Latest results › Supriya Lifescience Limited
Supriya Lifescience Limited Q2 FY27 results deck summary
NSE: SUPRIYA · BSE: 543434
Results deck of 6 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue rose 3.2% YoY to ₹2,063.0 mn, but EBITDA margin fell to 22.0% from 36.4%.
Key takeaways
- Q2 margin Q2 FY27 EBITDA margin fell to 22.0% from 36.4% in Q2 FY26, with EBITDA ₹454.0 mn against ₹726.5 mn.
- H1 revenue H1 FY27 revenue from operations ₹3,960.4 mn, up 14.8% YoY from ₹3,449.1 mn.
- QoQ revenue Q2 FY27 revenue ₹2,063.0 mn rose 8.7% over Q1 FY27 ₹1,897.5 mn, while EBITDA fell 4.3% to ₹454.0 mn.
- Ambernath launches Two new anesthetic liquid inhalation products were launched from Ambernath in Q2 FY27, with scale-up expected in coming quarters.
- Cost pressure Cost of goods sold rose 27.5% YoY in Q2 FY27 and other expenses 35.6%, against 3.2% revenue growth.
Supriya Lifescience Limited Q2 FY27 results
As filed: Revenue ₹206 cr (+3% year on year), EBITDA ₹45.4 cr (−37% year on year), PAT ₹29.3 cr (−42% year on year), EBITDA margin 22.0% (−1,000 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹190 cr (+31% year on year), EBITDA ₹47.5 cr (−7% year on year), PAT ₹24.0 cr (−31% year on year), EBITDA margin 25.0% (−1,000 bps). Score 30 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 1000 bps year on year. Tax rate 41%. Revenue fell 31% from last quarter. Share price after the results: +10.8% in 29 days (Nifty 500: −3.3%).
- Q4 FY26: Revenue ₹277 cr (+50% year on year), EBITDA ₹97.6 cr (+46% year on year), PAT ₹74.2 cr (+48% year on year), EBITDA margin 35.3% (−111 bps). Score 92 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin fell 111 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Profit rose ₹24.2 cr on a year ago, more than the ₹13.0 cr it added the year before. Share price after the results: +15.0% in 29 days (Nifty 500: +0.6%).
- Q3 FY26: Revenue ₹206 cr (+11% year on year), EBITDA ₹72.1 cr (+8% year on year), PAT ₹49.7 cr (+6% year on year), EBITDA margin 34.9% (−111 bps). Score 35 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 111 bps year on year. Share price after the results: −13.3% in 30 days (Nifty 500: −6.9%).
- Q2 FY26: Revenue ₹200 cr (+20% year on year), EBITDA ₹72.0 cr (+13% year on year), PAT ₹50.0 cr (+9% year on year), EBITDA margin 36.0% (−255 bps). Score 54 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 255 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹34.0 cr on a year ago, more than the ₹26.0 cr it added the year before. Share price after the results: −2.4% in 30 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹145 cr (−10% year on year), EBITDA ₹51.0 cr (−19% year on year), PAT ₹35.0 cr (−22% year on year), EBITDA margin 35.2% (−396 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 396 bps year on year. Revenue fell 21% from last quarter. Revenue rose ₹-16.0 cr on a year ago, against ₹29.0 cr the year before. Share price after the results: −1.3% in 30 days (Nifty 500: +2.2%).
- Q4 FY25: Revenue ₹184 cr (+16% year on year), EBITDA ₹67.0 cr (+20% year on year), PAT ₹50.0 cr (+35% year on year), EBITDA margin 36.4% (+97 bps). Score 48 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 97 bps year on year. Revenue rose ₹26.0 cr on a year ago, more than the ₹16.0 cr it added the year before. Share price after the results: −6.7% in 30 days (Nifty 500: +3.1%).
- Q3 FY25: Revenue ₹186 cr (+33% year on year), EBITDA ₹67.0 cr (+63% year on year), PAT ₹47.0 cr (+57% year on year), EBITDA margin 36.0% (+674 bps). Score 65 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 674 bps year on year. Profit rose ₹17.0 cr on a year ago, against ₹20.0 cr the year before.
Past price moves after results do not indicate future moves. Not a recommendation.
Supriya Lifescience Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (6 Nov 2026), Results deck (6 Nov 2026)
- Q1 FY27: Results deck (13 Aug 2026), Results press release (13 Aug 2026)
- Q4 FY26: Earnings call (28 May 2026), Results deck (27 May 2026)
- Q3 FY26: Earnings call (10 Feb 2026), Results deck (9 Feb 2026), Results press release (10 Feb 2026)
- Q2 FY26: Earnings call (13 Nov 2025), Results deck (12 Nov 2025), Results press release (13 Nov 2025)
- Q1 FY26: Results deck (13 Aug 2025), Results press release (14 Aug 2025)
- Q4 FY25: Results deck (27 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.